The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Amlodipine/Valsartan/Hydrochlorothiazide Rowex 10 mg/160 mg/25 mg Film-coated tablets

Rowex LtdPA0711/291/004

Main Information

Trade NameAmlodipine/Valsartan/Hydrochlorothiazide Rowex 10 mg/160 mg/25 mg Film-coated tablets
Active SubstancesAmlodipine besilate
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/291/004

Group Information

ATC CodeC09DX Angiotensin II antagonists, other combinations
C09DX01 valsartan, amlodipine and hydrochlorothiazide


License statusAuthorised
Licence Issued19/08/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back